Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche’s Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug

Drug Shows Interim OS Gain – But Will It Be Enough?

Executive Summary

An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.

You may also be interested in...

Vabysmo’s Lift Off Gives Roche Time For Pipeline Renewal

The company’s new blockbuster eye treatment helped it maintain growth in 2023, while 2024 will see more strategic updates as the company broadens its disease area focus.

Will CEO’s New Strategy Boost Roche’s Phase III Success?

Six months after taking the reins, Thomas Schinecker has unveiled a new approach aimed at preserving Roche’s 'R&D diversity' while cutting costly Phase III failures.

Trial Success Sets Up Roche’s Alecensa To Be First ALK+ Drug In Adjuvant NSCLC

Roche has suffered many setbacks in its NSCLC pipeline, so clear signs of Phase III success from Alecensa in the adjuvant setting are welcome for the company.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts